Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia

Journal of the Royal College of Physicians of Edinburgh

Volumn 41, Issue 2, 2011, Pages 117-118

  Ducas, R A ^a   Seftel, M D ^a   Ducas, J ^a   Seifer, C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Arrhythmia; Arsenic trioxide; Promyelocytic leukaemia

Indexed keywords

ARSENIC TRIOXIDE; MAGNESIUM; METOPROLOL; POTASSIUM;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; MONOMORPHIC VENTRICULAR TACHYCARDIA; POTASSIUM BLOOD LEVEL; PROMYELOCYTIC LEUKEMIA; QT INTERVAL;

ADULT; ANTI-ARRHYTHMIA AGENTS; ANTINEOPLASTIC AGENTS; ARSENICALS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAGNESIUM; MANITOBA; METOPROLOL; OXIDES; POTASSIUM; TACHYCARDIA, VENTRICULAR;

EID: 80052705447     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2011.204     Document Type: Article

References (5)

1. Au WY, Kwong YL. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin 2008; 29:296-304. doi:10.1111/j.1745-7254.2008.00771.x
2. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53:2231-47. doi:10.1016/j.jacc.2009.02.050
3. Unnikrishnan D, Dutcher JP, Varshneya N et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97:1514-6. doi:10.1182/blood.V97.5.1514
4. Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2004; 109:26-9. doi:10.1161/01.CIR.0000109484.00668.CE
5. O'Donnell MR, Appelbaum FR, Coutre SE et al. NCCN clinical practice guideline in oncology: acute myeloid leukemia. National Comprehensive Cancer Network; 2010. Available from: http://www.cancerplan.net/Best%20Practise/aml.pdf